# US 2012/0253008 A1 · Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0253008 A1
- Document ID: US20120253008A1
- Status: Published application
- Kind: A1
- Application number: 13/495,120
- Filed: 2012-06-13
- Published: 2012-10-04
- Earliest claimed: 2008-04-17
- Assignees: Ablynx N.V.
- Inventors: Hilde Adi Pierrette Revets; Carlo Boutton; Stephanie Staelens; Peter Verheesen
- Web page: https://patentgrep.com/patent/US20120253008A1

## CPC

- C07K 16/32: against translation products of oncogenes
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- C07K 14/765: Serum albumin, e.g. HSA
- C07K 16/36: against blood coagulation factors
- C07K 2317/22: from camelids, e.g. camel, llama or dromedary
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K 2319/31: fusions, other than Fc, for prolonged plasma life, e.g. albumin
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to amino acid sequences that are capable of binding to serum proteins; to compounds, proteins, polypeptides, fusion proteins or constructs comprising or essentially consisting of such amino acid sequences; to nucleic acids that encode such amino acid sequences, compounds, proteins, polypeptides, fusion proteins or constructs; to compositions, and in particular pharmaceutical compositions, that comprise such amino acid sequences, compounds, proteins, polypeptides, fusion proteins or constructs; and to uses of such amino acid sequences, compounds, proteins, polypeptides, fusion proteins or constructs.

## Claims

### Claim 1

An isolated amino acid sequence that specifically binds human serum albumin and that comprises:
(i) an Arg (R) residue that forms a hydrogen bond with the amino acid residues Asn (N) 133 & Asn (N) 135 of human serum albumin and/or forms electrostatic interactions with the main-chain oxygen atoms of the Pro (P) 134 and Leu (L) 136 residues of human serum albumin; and
(ii) a Trp (W) residue that forms electrostatic interactions with the Arg (R) 138 residue of human serum albumin.

### Claim 2 (depends on 1)

The isolated amino acid sequence according to claim 1, that comprises:
(i) a sequence motif RXWD, in which R is arginine, X may be any amino acid, W is tryptophan, and D is aspartic acid; and/or
(ii) a sequence motif GGG, in which G is glycine.

### Claim 3 (depends on 2)

The isolated amino acid sequence according to claim 2, wherein in the sequence motif RXWD, X is tryptophan (W), tyrosine (Y), phenylalanine (F), serine (S) or aspartic acid (D).

### Claim 4 (depends on 2)

The isolated amino acid sequence according to claim 2, wherein the amino acid sequence comprises sequence motif RXWD and GGG.

### Claim 5 (depends on 2)

The isolated amino acid sequence according to claim 2, that comprises:
(i) the sequence motif RXWD, in which R is arginine, X may be any amino acid, W is tryptophan, and D is aspartic acid; and/or
(ii) a sequence motif FGGG (SEQ ID NO:120), in which F is phenylalanine and G is glycine.

### Claim 6 (depends on 5)

The isolated amino acid sequence according to claim 5, wherein in the sequence motif RXWD, X is tryptophan (W), tyrosine (Y), phenylalanine (F), serine (S) or aspartic acid (D).

### Claim 7 (depends on 5)

The isolated amino acid sequence according to claim 5, wherein the amino acid sequence comprises sequence motif RXWD and FGGG (SEQ ID NO:120).

### Claim 8 (depends on 5)

The isolated amino acid sequence according to claim 5, that comprises
(i) the sequence motif RXWD, in which R is arginine, X may be any amino acid, W is tryptophan, and D is aspartic acid; and/or
(ii) a sequence motif DVFGGG (SEQ ID NO:129), in which D is aspartic acid, V is valine, F is phenylalanine and G is glycine.

### Claim 9 (depends on 8)

The isolated amino acid sequence according to claim 8, wherein in the sequence motif RXWD, X is tryptophan (W), tyrosine (Y), phenylalanine (F), serine (S) or aspartic acid (D).

### Claim 10 (depends on 8)

The isolated amino acid sequence according to claim 8, wherein the amino acid sequence comprises sequence motif RXWD and DVFGGG (SEQ ID NO:129).

### Claim 11 (depends on 1)

The isolated amino acid sequence according to claim 1 that:
a) has no more than 9 amino acid differences over the full length of the isolated amino acid sequence with the amino acid sequence AASYSDYDVFGGGTDFGP (SEQ ID NO:1);
and that:
b) binds better to human serum albumin than the amino acid sequence AASYSDYDVFGGGTDFGP (SEQ ID NO:1).

### Claim 12 (depends on 11)

The isolated amino acid sequence according to claim 11, in which, compared to the amino acid sequence of SEQ ID NO.1:
the serine residue (S) at position 3 of SEQ ID NO:1 is replaced by an amino acid residue chosen from arginine (R), proline (P), phenylalanine (F), tyrosine (Y), tryptophan (W), histidine (H), leucine (L), isoleucine (I), valine (V) or methionine (M);
and/or
the serine residue (S) at position 5 of SEQ ID NO:1 is replaced by an amino acid residue chosen from arginine (R), proline (P), phenylalanine (F), tyrosine (Y), tryptophan (W) or histidine (H);
and/or
the aspartate residue (D) at position 15 of SEQ ID NO:1 is replaced by an amino acid residue chosen from proline (P), alanine (A), glycine (G), serine (S) or threonine (T);
and/or
the phenylalanine residue (F) at position 16 of SEQ ID NO:1 is replaced by proline (P), leucine (L), isoleucine (I), valine (V), methionine (M), alanine (A), glycine (G), serine (S) or threonine (T);
and/or
the proline residue (P) at position 18 of SEQ ID NO:1 is maintained or replaced by aspartic acid (D), glutamic acid (E), glutamine (Q), asparagine (N), alanine (A), glycine (G), serine (S) or threonine (T);
and which amino acid sequence optionally comprises one or more further suitable amino acid insertions, deletions and/or substitutions.

### Claim 13 (depends on 11)

The isolated amino acid sequence according to claim 11, that comprises:
(i) a sequence motif RXWD, in which R is arginine, X may be any amino acid, W is tryptophan, and D is aspartic acid; and/or
(ii) a sequence motif GGG in which G is glycine.

### Claim 14 (depends on 5)

The isolated amino acid sequence according to claim 5, wherein in the sequence motif RXWD, X is tryptophan (W), tyrosine (Y), phenylalanine (F), serine (S) or aspartic acid (D).

### Claim 15 (depends on 5)

The isolated amino acid sequence according to claim 5, wherein the amino acid sequence comprises sequence motif RXWD and GGG.

### Claim 16 (depends on 13)

The isolated amino acid sequence according to claim 13, that comprises:
(i) the sequence motif RXWD, in which R is arginine, X may be any amino acid, W is tryptophan, and D is aspartic acid; and/or
(ii) a sequence motif FGGG (SEQ ID NO:120) in which F is phenylalanine and G is glycine.

### Claim 17 (depends on 16)

The isolated amino acid sequence according to claim 16, wherein in the sequence motif RXWD, X is tryptophan (W), tyrosine (Y), phenylalanine (F), serine (S) or aspartic acid (D).

### Claim 18 (depends on 16)

The isolated amino acid sequence according to claim 16, wherein the amino acid sequence comprises sequence motif RXWD and FGGG (SEQ ID NO:120).

### Claim 19 (depends on 16)

The isolated amino acid sequence according to claim 16, that comprises
(i) the sequence motif RXWD, in which R is arginine, X may be any amino acid, W is tryptophan, and D is aspartic acid; and/or
(ii) a sequence motif DVFGGG (SEQ ID NO:129) in which D is aspartic acid, V is valine, F is phenylalanine and G is glycine.

### Claim 20 (depends on 19)

The isolated amino acid sequence according to claim 19, wherein in the sequence motif RXWD, X is tryptophan (W), tyrosine (Y), phenylalanine (F), serine (S) or aspartic acid (D).

### Claim 21 (depends on 19)

The isolated amino acid sequence according to claim 19, wherein the amino acid sequence comprises sequence motif RXWD and DVFGGG (SEQ ID NO:129).

### Claim 22 (depends on 1)

The isolated amino acid sequence according to claim 1, wherein said amino acid sequence is such that, when it is linked or fused to a therapeutic moiety, compound, protein or other therapeutic entity, the compound thus obtained has a longer half-life than a corresponding compound or construct in which said therapeutic moiety, compound, protein or other therapeutic entity is linked or fused to the amino acid sequence of SEQ ID NO:1; and preferably has a half-life that is the same or longer than a corresponding compound or construct in which said therapeutic moiety, compound, protein or other therapeutic entity is linked or fused to the amino acid sequence of SEQ ID NO:14.

### Claim 23 (depends on 1)

The isolated amino acid sequence according to claim 1, that is cross-reactive with serum albumin from cynomolgus monkeys (Macaca fascicularis).

### Claim 24 (depends on 1)

A compound or construct which comprises at least one amino acid sequence according to claim 1 and at least one therapeutic moiety.

### Claim 25 (depends on 1)

A compound or construct which comprises at least two amino acid sequences according to claim 1 and at least one therapeutic moiety.

### Claim 26 (depends on 1)

A compound or construct which comprises at least one tandem repeat comprising at least two amino acid sequences according to claim 1 and at least one therapeutic moiety.
